Investigation for Clinical Efficacy and Safety of Ipragliflozin 50mg and 100mg on Type II Diabetes

NCT02317484 · clinicaltrials.gov ↗

COMPLETED

Status

231

Enrollment

OTHER

Sponsor class

Conditions

Diabetes Mellitus, Type 2

Interventions

DRUG: Ipragliflozin (SGLT2 inhibitor)

Sponsor

Translational Research Center for Medical Innovation, Kobe, Hyogo, Japan

Collaborators

[object Object]
[object Object]